Brad is the Director of Manufacturing Sciences and Technology at Emergent BioSolutions Single-Use cGMP Multi-Product Drug Substance Manufacturing Facility in Baltimore, Maryland. Brad joined Emergent from Lonza in 2010 as the 2nd site employee and led the retrofit of the microbial facility (previously owned by Cambrex) to create the multi-product, multi-platform, multi-scale facility that received the CIADM designation in 2012. Prior to Emergent, Mr. Sepp held similar process engineering positions and leadership roles at Lonza including brownfield construction of an R&D facility, process transfer and bioreactor automation. Throughout his 20 year career in cGMP drug substance manufacturing and development, Mr. Sepp has a successful track record in facility startup, facility design, industrial automation and engineering project management. He has been an ISPE member since 2004, has a Bioengineering degree from Illinois and a Masters in Microbial Engineering from the University of Minnesota.